A Clinical Trial of Sacituzumab Tirumotecan (MK-2870) with Pembrolizumab (MK-3475)
Phase 3
1,023
about 5.9 years
18+
Female only
8 sites in FL, LA, NV +4
What this study is about
This trial is testing a new treatment for cervical cancer. It involves giving sacituzumab tirumotecan, pembrolizumab, and bevacizumab together to people whose cervical cancer has spread. The goal is to see if this combination is safe and effective compared to standard treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Bevacizumab
- 2.Receive Pembrolizumab
- 3.Receive Sacituzumab Tirumotecan
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab, carboplatin, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion, injection, intravenous
Primary: Part 1 Safety Run-in: Number of Participants Who Discontinue Study Treatment Due to an AE, Part 1 Safety Run-in: Number of Participants Who Experience One or More Adverse Events (AEs), Part 2 Maintenance Treatment: Overall Survival (OS), Part 2 Maintenance Treatment: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Secondary: Part 2 Maintenance Treatment: Change from Baseline in EORTC QLQ-C30 Physical Functioning Combined Score, Part 2 Maintenance Treatment: Change from Baseline in EORTC QLQ-C30 Role Functioning Combined Score, Part 2 Maintenance Treatment: Change from Baseline in EORTC Quality of Life Questionnaire-Cervical Cancer Module (QLQ-CX24) Combined Score, Part 2 Maintenance Treatment: Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status and Quality of Life Combined Score, Part 2 Maintenance Treatment: Number of Participants Who Discontinue Study Treatment Due to an AE, Part 2 Maintenance Treatment: Number of Participants Who Experience One or More AEs, Part 2 Maintenance Treatment: Progression-free Survival 2 (PFS2) as Assessed by the Investigator
Oncology